Reproducibility Initiative Shrinks

Budget issues are limiting the number of studies the Reproducibility Project: Cancer Biology will try to re-do.

By | December 3, 2015

WIKIMEDIA, NATIONAL CANCER INSTITUTEThe Reproducibility Project: Cancer Biology originally intended to replicate 50 high-impact cancer papers in an effort to get some sense of how often scientific results are repeatable. But as Nature News reported yesterday (December 2), that number is scaling back to 37.

According to the news report, the project had estimated each study would cost $25,000 to $35,000, but as things got moving the costs became closer to $40,000 per replicated study.

“I don’t think that was truly appreciated at the beginning of the project,” Tim Errington, a project manager at the Center for Open Science, which is coleading the project, told Nature News. “The best thing for us to do is move forward with what we have.”

The 13 culled papers hadn’t made much progress so far and included animal experiments, which can be expensive.

Some expressed disappointment at the reduction. “Bad news, was looking forward to this,” @PubPeer tweeted. Others have criticized the reproducibility initiative for being marked with “a naiveté that by simply embracing this ethic, which sounds eminently reasonable, that one can clean out the Augean stables of science,” the Whitehead Institute’s Robert Weinberg, whose study was cut from the list, told Nature News.


Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Immune Checkpoint Found Lacking in Type 1 Diabetes
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.